43E0 Stock Chart & Stats
€7.95
-€0.05(-0.94%)
At close: 4:00 PM EDT
€7.95
-€0.05(-0.94%)
Day’s Range― - ―
52-Week Range€3.54 - €9.15
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€73.90M
Enterprise Value€80.77
Total Cash (Recent Filing)€10.04M
Total Debt (Recent Filing)€9.56M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Oct 29, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding9,015,885
10 Day Avg. Volume46
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)-22.29
Price to Sales (P/S)1.19
P/FCF Ratio-4.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.87Price Target Upside61.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.2
Revenue Forecast (FY)€36.14M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthMulti-year revenue scaling indicates increasing adoption of the company’s neuromodulation products. Reaffirmed 2026 growth guidance and strong VA, consumer and Quell channels support continued expansion over the next several quarters.
High Gross Margin And Improving LeverageVery high gross margins provide a strong foundation for eventual profitability as revenue scales. The narrower adjusted EBITDA loss suggests operating expenses may be gaining leverage, although sustained execution is needed to reach breakeven.
Multiple Product And Federal Growth ChannelsGrowth across VA prescriptions, consumer wellness and Quell reduces reliance on a single commercialization path. Federal expansion, product rollouts and the next-generation platform provide identifiable avenues for broader long-term adoption.
Bears Say
Persistent Operating LossesThe company has not yet converted strong gross margins into operating profitability, meaning expenses continue to exceed gross profit. Persistent losses could limit reinvestment capacity and require additional financing before scale produces sustainable earnings.
Cash Burn And Financing SensitivityNegative operating and free cash flow indicate that growth still consumes substantial capital. Declining liquidity increases dependence on external funding and makes execution more sensitive to delays in reaching breakeven or expanding reimbursement-supported demand.
Weak Balance Sheet FlexibilityNegative equity and higher debt reduce financial flexibility relative to the company’s modest asset base. Further losses or investment needs could increase refinancing risk, constrain strategic options and dilute existing holders if new capital is required.
Electrocore News
43E0 FAQ
What was Electrocore Llc’s price range in the past 12 months?
Electrocore Llc lowest stock price was €3.54 and its highest was €9.15 in the past 12 months.
What is Electrocore Llc’s market cap?
Electrocore Llc’s market cap is €73.90M.
When is Electrocore Llc’s upcoming earnings report date?
Electrocore Llc’s upcoming earnings report date is Oct 29, 2026 which is in 56 days.
How were Electrocore Llc’s earnings last quarter?
Electrocore Llc released its earnings results on Aug 06, 2026. The company reported -€0.283 earnings per share for the quarter, beating the consensus estimate of -€0.362 by €0.079.
Is Electrocore Llc overvalued?
According to Wall Street analysts Electrocore Llc’s price is currently Undervalued.
Does Electrocore Llc pay dividends?
Electrocore Llc does not currently pay dividends.
What is Electrocore Llc’s EPS estimate?
Electrocore Llc’s EPS estimate is -0.23.
How many shares outstanding does Electrocore Llc have?
Electrocore Llc has 9,015,885 shares outstanding.
What happened to Electrocore Llc’s price movement after its last earnings report?
Electrocore Llc reported an EPS of -€0.283 in its last earnings report, beating expectations of -€0.362. Following the earnings report the stock price went up 4.587%.
Which hedge fund is a major shareholder of Electrocore Llc?
Currently, no hedge funds are holding shares in DE:43E0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Electrocore Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€12.87 (61.85% Upside)
€12.87 (61.85% Upside)
Blogger Sentiment
Bearish
DE:43E0 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $694.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Electrocore Llc
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
43E0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong quarter of execution: record revenue, significant YoY growth, higher gross margins (87%), and meaningful improvement in adjusted EBITDA loss, all while reaffirming full-year guidance. Management also highlighted multiple catalysts (VA and DoD expansion, TruVega international launch, Quell OTC relaunch, R&D/clinical progress including PTSD work) and added experienced commercial leadership. Key risks discussed include a decrease in cash balances, Q1 seasonal cash burn and near-term capital timing, ongoing GAAP losses driven by nonrecurring charges, concentrated product penetration in the VA (only ~2.5%), and historically variable TACSTIM revenue. On balance, the positives around accelerating revenue, margin expansion, improving adjusted EBITDA, product and channel momentum, and clear operational priorities outweigh the near-term financial and execution risks presented on the call.View all DE:43E0 earnings summaries43E0 Stock 12 Month Forecast
Average Price Target
€12.87
▲(61.85% Upside)
Technical Analysis
Myomo
―
Modular Medical
―
NeuroOne Medical Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―